AI Terminal
Isofol Medical
Pre-Annual General Meeting Information • May 12, 2025
3063_rns_2025-05-12_7c1a8153-51e6-4f63-9821-f557ac844f70.pdf
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
The information in the press release is intended for investors.
Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, May 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Extraordinary General Meeting on Wednesday, June 11, 2025.
The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the extraordinary general meeting held on Wednesday, June 11, 2025 at 1 p.m. at Advokatfirman Vinge office, Nordstadstorget 6, 8th floor, Gothenburg. Registration starts at 12:30 p.m. and ends when the meeting convenes.
The complete notice and instructions on how to attend the meeting is available in Swedish on the company´s website, www.isofolmedical.com
For further information, please contact
Isofol Medical AB (publ) Petter Segelman Lindqvist, verkställande direktör E-mail: [email protected] Telephone: +46 (0)739 60 12 56
Margareta Hagman, CFO E-mail: [email protected] Telephone: +46 (0)738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 08:45 CEST on May 12, 2025.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.